2025-12-29 - Analysis Report
Okay, here's a comprehensive report on Tempus AI Inc. (TEM) based on the provided data, broken down into simple numbers, analysis, and a comprehensive summary.

**1. Return Rate Comparison**

*   **TEM:** Cumulative Return = 11.92%
*   **S&P 500 (VOO):** Cumulative Return = 32.43%
*   **Divergence:** -15.0
*   **Relative Divergence:** 22.3
*   **Company Overview:** Tempus AI Inc. is a technology company focused on precision medicine, using AI and data to personalize healthcare.

**Analysis:**

*   TEM has significantly underperformed the S&P 500, with a -15.0 divergence in cumulative returns.
*   The relative divergence of 22.3 suggests the divergence is near the lower end of its historical range. This means the current underperformance isn't the *worst* it's been, but it is still significant.

**Alpha, Beta Analysis**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2023-2025  | 12.0% | 76.7% | -20.0% | 0.3 | 11.2 |

**Analysis:**
* CAGR (Compound Annual Growth Rate) of 12% is decent, but the MDD (Maximum Drawdown) of 76.7% is alarming, indicating high volatility and risk.
*  A negative Alpha (-20.0%) shows underperformance compared to a benchmark, even after adjusting for risk.
* A Beta of 0.3 indicates that TEM's price is theoretically 30% as volatile as the market.
* Cap(B) stands for market capitalization of TEM.

**2. Recent Stock Price Fluctuations**

*   **Current Close:** 62.70
*   **Previous Close:** 64.26
*   **Change:** -2.43 (-3.78% as displayed on the last market)
*   **5-day SMA:** 64.41
*   **20-day SMA:** 70.72
*   **60-day SMA:** 78.98

**Analysis:**

*   TEM is trading below its 5-day, 20-day, and 60-day Simple Moving Averages (SMAs), suggesting a short-term, medium-term, and long-term downtrend.
*   The recent price decline suggests increasing downward momentum.

**3. Technical Indicators and Signals**

*   **Market Risk Indicator (MRI):** 1.0 (High Investment Recommended)
*   **RSI:** 18.47 (Oversold)
*   **PPO:** -0.95
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (14 shares - Very Safe - MRI:0.90) Monthly invest 5.0% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Relative Divergence Change (20 days):** -9.7 (decreasing)
*   **Expected Return (%):** NaN (Not a Number - implying unavailable or unreliable data)

**Analysis:**

*   The RSI of 18.47 indicates that TEM is significantly oversold, which *could* suggest a potential for a price rebound. However, oversold conditions can persist.
*   PPO (Percentage Price Oscillator) being negative suggests that short-term momentum is weaker than long-term momentum.
*   The hybrid signal recommends buying, however, the MRI indicator does not reflect the current issues and decline of TEM. It should be considered only a small portion of investment
*   The decreasing relative divergence change reinforces the recent underperformance.

**4. Recent News & Significant Events**

*   **FDA Clearance & Price Drop:** Concerns surrounding opinions on FDA clearance and price drop.
*   **Positive Year Performance (Up 87% YTD):**  Conflicting with current price action; historical performance may not be indicative of future results.
*   **Market Fluctuations Amid Strategic Moves:** Highlights volatility and uncertainty.
*   **Buy, Hold, or Sell Decision:** Indicates ongoing debate about TEM's investment potential.
*   **Regulatory Pricing Catch-Up:**  Suggests potential upside if the company can successfully navigate regulatory hurdles.
*   **Insider Selling:**  CEO selling a significant number of shares can be perceived negatively by the market.

**4.2 Analyst Opinions**

*   **Consensus:** Buy (~2.14)
*   **Target Price:** Average $88.92 (Significant upside from current price)
*   **Recent Rating Changes:** None provided (no recent upgrades or downgrades)

**Analysis:**

*   Analysts generally have a "Buy" rating and a target price well above the current trading price, suggesting they believe TEM is undervalued. However, analyst ratings should be viewed with skepticism and balanced against other information.

**5. Comprehensive Analysis**

Tempus AI (TEM) presents a mixed picture.

**Negative Factors:**

*   **Significant Underperformance:**  TEM has significantly underperformed the S&P 500.
*   **Technical Downtrend:** Trading below key moving averages.
*   **Negative Alpha:** Indicating underperformance relative to risk.
*   **Insider Selling:** A potential cause for concern.
*   **High Volatility:** Evidenced by the high MDD.
*   **Recent Price Decline:** Indicates downward momentum and market uncertainty.

**Positive Factors:**

*   **Oversold Condition:**  RSI suggests a potential for a rebound.
*   **Analyst "Buy" Ratings:** Analysts generally view the stock favorably with significant upside potential.
*   **Potential for Regulatory Catch-Up:**  If successful, this could be a catalyst for growth.
*   **High MRI:** Recommends high investment, however, caution is advised for this indicator.

**Conclusion:**

Investing in TEM is currently *high risk*. While analysts are generally positive and the RSI indicates an oversold condition, the recent underperformance, insider selling, and high volatility should give investors pause.

**Recommendations:**

*   **Caution is advised.** Investors should conduct thorough due diligence before investing in TEM.
*   **Monitor key developments.** Pay close attention to regulatory news, company announcements, and insider trading activity.
*   **Consider a small position.** If you believe in the long-term potential, consider a small, speculative position that you are willing to lose.
*   **Be aware of volatility.** TEM is likely to experience significant price swings.

**Disclaimer:** I am an AI chatbot and cannot provide financial advice. This analysis is for informational purposes only and should not be considered a recommendation to buy or sell TEM stock.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.